Home/Filings/4/0001104659-23-095017
4//SEC Filing

Duey Marc 4

Accession 0001104659-23-095017

CIK 0001781983other

Filed

Aug 23, 8:00 PM ET

Accepted

Aug 24, 9:50 PM ET

Size

26.2 KB

Accession

0001104659-23-095017

Insider Transaction Report

Form 4
Period: 2023-08-23
Duey Marc
Director
Transactions
  • Conversion

    Series A Non-Voting Convertible Preferred Stock

    2022-08-231,1610 total(indirect: By Spouse)
    Exercise: $0.00Common Stock (11,610 underlying)
  • Conversion

    Series A Non-Voting Convertible Preferred Stock

    2022-08-23400,9690 total
    Exercise: $0.00Common Stock (4,009,690 underlying)
  • Conversion

    Common Stock

    2022-08-23+4,009,6904,167,589 total
  • Award

    Stock Options (Right to Buy)

    2023-08-23+2,0002,000 total
    Exercise: $3.65Exp: 2033-08-23Common Stock (2,000 underlying)
  • Award

    Common Stock

    2023-08-23+500208,878 total
  • Conversion

    Common Stock

    2022-08-23+11,610602 total(indirect: By Spouse)
Footnotes (5)
  • [F1]These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
  • [F2]Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023
  • [F3]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
  • [F4]Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock ("Common Stock") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date.
  • [F5]The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Issuer

Aprea Therapeutics, Inc.

CIK 0001781983

Entity typeother

Related Parties

1
  • filerCIK 0001925150

Filing Metadata

Form type
4
Filed
Aug 23, 8:00 PM ET
Accepted
Aug 24, 9:50 PM ET
Size
26.2 KB